Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial

Overview of attention for article published in Cancers, March 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 20 Dimensions

Readers on

mendeley: 22 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 5 X posts from 4 X users, with an upper bound of 2,334 followers.

#肺癌 #アテゾリズマブA IM150の事後解析、ABPC vs BPC。免疫療法予後予測因子としてリンパ球好中球比>3、LDH>基準値、により3群に分けた。カプランは綺麗に分離。特にpoorリスク群はA上乗せ効果が乏しい。ABPCは毒性強い治療だし、poor群は無理できないと考える事は出来る。 https://t.co/JJZBTCRsFx

21 Sep 2021

Reply Repost Favourite

Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezoli… https://t.co/qD45B7WHiW

07 Apr 2021

Reply Repost Favourite

RT @pmg_flinders: A new publication by Dr Ashley Hopkins on the value of the Lung Immune Prognostic Index in Patients with Non-Small Cell L…

22 Mar 2021

Reply Repost Favourite

RT @pmg_flinders: A new publication by Dr Ashley Hopkins on the value of the Lung Immune Prognostic Index in Patients with Non-Small Cell L…

22 Mar 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.